98 related articles for article (PubMed ID: 10602446)
1. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state.
Kiraz S; Ertenli I; Benekli M; Haznedaroğlu IC; Calgüneri M; Celik I; Apraş S; Kirazli S
Lupus; 1999; 8(9):737-41. PubMed ID: 10602446
[TBL] [Abstract][Full Text] [Related]
2. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA
Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
[TBL] [Abstract][Full Text] [Related]
3. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.
el-Gamal YM; Heshmat NM; el-Kerdany TH; Fawzy AF
Pediatr Allergy Immunol; 2004 Jun; 15(3):270-7. PubMed ID: 15209962
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
5. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.
Pereira J; Alfaro G; Goycoolea M; Quiroga T; Ocqueteau M; Massardo L; Pérez C; Sáez C; Panes O; Matus V; Mezzano D
Thromb Haemost; 2006 Jan; 95(1):94-9. PubMed ID: 16543967
[TBL] [Abstract][Full Text] [Related]
6. Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis.
Inoh M; Tokuda M; Kiuchi H; Kurata N; Takahara J
Arthritis Rheum; 1996 Feb; 39(2):287-91. PubMed ID: 8849381
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus.
Ho CY; Wong CK; Li EK; Tam LS; Lam CW
Rheumatology (Oxford); 2003 Jan; 42(1):117-22. PubMed ID: 12509624
[TBL] [Abstract][Full Text] [Related]
9. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.
Frijns CJ; Derksen RH; De Groot PG; Algra A; Fijnheer R
Clin Exp Immunol; 2001 Jul; 125(1):149-54. PubMed ID: 11472438
[TBL] [Abstract][Full Text] [Related]
10. Plasma thrombomodulin and alpha 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus.
Kawakami M; Kitani A; Hara M; Harigai M; Suzuki K; Kawaguchi Y; Ishii H; Kazama M; Kawagoe M; Nakamura H
J Rheumatol; 1992 Nov; 19(11):1704-9. PubMed ID: 1337109
[TBL] [Abstract][Full Text] [Related]
11. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.
Frijns R; Fijnheer R; Schiel A; Donders R; Sixma J; Derksen R
J Rheumatol; 2001 Mar; 28(3):514-9. PubMed ID: 11296951
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases.
Kotajima L; Aotsuka S; Sato T
Clin Exp Rheumatol; 1997; 15(1):59-65. PubMed ID: 9093774
[TBL] [Abstract][Full Text] [Related]
13. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus.
Svenungsson E; Cederholm A; Jensen-Urstad K; Fei GZ; de Faire U; Frostegård J
Scand J Rheumatol; 2008; 37(5):352-9. PubMed ID: 18666029
[TBL] [Abstract][Full Text] [Related]
14. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
[TBL] [Abstract][Full Text] [Related]
15. Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus.
Cicarini WB; Duarte RCF; Ferreira KS; Loures CMG; Consoli RV; Neiva CLS; de Pádua PM; Nunes FFC; Alves LCV; Reis EA; Moreira CC; Guimarães TMPD; de Toledo VPCP; Carvalho MDG
Lupus; 2020 Feb; 29(2):182-190. PubMed ID: 31948350
[TBL] [Abstract][Full Text] [Related]
16. Effect of disease activity and corticosteroids on serum levels of soluble endothelial cell protein C receptor in patients with systemic lupus erythematosus.
Koarada S; Tsuneyoshi N; Haruta Y; Tada Y; Mitamura M; Inoue H; Ohta A; Fukudome K; Nagasawa K
Mod Rheumatol; 2009; 19(2):173-9. PubMed ID: 19067109
[TBL] [Abstract][Full Text] [Related]
17. Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients.
Bugała K; Mazurek A; Gryga K; Komar M; Kopeć G; Musiał J; Podolec P; Perricone C; Płazak W
Clin Rheumatol; 2018 Aug; 37(8):2087-2093. PubMed ID: 29675623
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the thrombin generation profile in systemic lupus erythematosus.
Kern A; Barabás E; Balog A; Burcsár S; Kiszelák M; Vásárhelyi B
Physiol Int; 2017 Mar; 104(1):35-41. PubMed ID: 28361572
[TBL] [Abstract][Full Text] [Related]
19. Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
Brenner B; Tavori S; Lerner M; Tatarsky I; Lorber M
Isr J Med Sci; 1992 Jan; 28(1):9-15. PubMed ID: 1733904
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
Figueredo MA; Rodriguez A; Ruiz-Yagüe M; Romero M; Fernandez-Cruz A; Gomez-de la Concha E; Patiño R
J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
